|
Evaluation of New Test Method to Measure Kidney Function Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Evaluation of New Test Method to Measure Kidney Function conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Evaluation of New Test Method to Measure Kidney Function Clinical research trials and Evaluation of New Test Method to Measure Kidney Function medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Evaluation of New Test Method to Measure Kidney Function. Evaluation of New Test Method to Measure Kidney Function Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Evaluation of New Test Method to Measure Kidney Function clinical trial. Participants frequently get the best healthcare available for their Evaluation of New Test Method to Measure Kidney Function condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation of New Test Method to Measure Kidney Function  Evaluation of New Test Method to Measure Kidney Function
Evaluation of New Test Method to Measure Kidney Function
For Condition: Kidney Disease
Status: Completed
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: This study will test the accuracy of a new "Fast GFR" (glomerular filtration rate) test to evaluate kidney function. Accurate assessment of kidney function is important in many clinical situations, including detecting kidney disease early, determining appropriate drug dosages, deciding when to begin dialysis, and evaluating heart and kidney organ donors and recipients. The current GFR test is used mostly for research purposes, as it is too costly and complicated for general medical use. Another significant drawback to its use in diagnosing acute kidney failure is the time it takes (3 to 24 hours) to complete, since effective therapy for this condition requires its detection as soon as possible. The Fast GFR, by comparison, takes only 45 minutes. Patients 6 years old and older with kidney disease or with impaired kidney function caused by abnormal heart function or swelling-from congestive heart failure, severe infections, swelling from fluid accumulation, fluid in the abdomen, or burns-may be eligible for this study. Patients will undergo both the standard and the Fast GFR tests, described below, to evaluate the accuracy of the new test. Fast GFR: Two catheters (thin flexible tubes) are placed into two arm veins, one for injecting iothalamate-an agent commonly used in CT scanning and blood vessel imaging-and the other for collecting blood samples. Baseline blood and urine samples are collected and then 0.5 milliliter (ml) iothalamate is injected into a vein. Blood samples are collected at 5, 10, 15, 20, 30, and 45 minutes in adults and at 5, 15, and 45 minutes in children. Urine is collected at 45 minutes. The size of the bladder is measured using ultrasound to determine if the bladder has completely emptied. Standard GFR: Iothalamate (1 ml) is injected under the skin. Blood samples are collected at 60, 90, 120, 180 and 240 minutes. (A heparin lock is used to avoid multiple needle sticks.) Urine is collected at 60, 90, 120, 180 and 240 minutes. The size of the bladder is measured using ultrasound to determine if the bladder has completely emptied.
Details: Accurate measurement of renal function is required to detect and treat renal dysfunction. The glomerular filtration rate (GFR) is the most widely used test to measure renal function in research studies. However, current GFR tests are lengthy, costly, and too complicated for general use in clinical settings. At the present time, therapies for acute renal failure are generally unsatisfactory. However, it is likely that effective therapy will need to be given early in the course of acute renal failure. We recently developed a simple Fast intravenous GFR test that can be performed in 45 minutes that may assist in identification of patients with the earliest stages of acute renal failure. This test has been validated in ambulatory adults with chronic renal failure. The current protocol will compare the fast intravenous GFR test to a reference standard subcutaneous GFR method in patients with acute renal failure, sepsis, congestive heart failure, edema, or chronic renal failure.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Both male and female subjects will be recruited without regard to race or ethnic origin. Suspected renal dysfunction based upon: Acute renal failure with elevated serum creatinine (at least 50% increase within 24 hours preceding enrollment) without stabilization or recovery, despite optimization of hemodynamic fluid status and correction of any known pharmacologic, pre-renal, or post-renal etiologic factors, or Congestive heart failure by clinical criteria (rales, S3, pedal edema on clinical exam), or Edema or ascites (by clinical exam), or Sepsis or septic physiology (shock or hyperdynamic circulation, suspected sepsis), or Chronic Renal Failure (creatinine greater than 1.3). Patients older than 18 years old who provide their own informed consent. Patients younger than 18 but at least 6 years old whose parent or legal guardian can provide informed consent. EXCLUSION CRITERIA: Inability to cooperate with the study. Known allergy to iothalamate or other iodine containing compounds. Urinary tract obstruction. Pregnant women or lactating mothers. Patients in whom vascular access cannot be secured.
Total Enrollment: 150
Location and Contact Information:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 000148; 00-DK-0148
Study Start Date: June 9, 2000
Record last reviewed: June 6, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026715
Other Kidney Disease Studies:
1. Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy
2. Oxaliplatin in Cancer Patients with Impaired Kidney Function
3. MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery
4. Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
5. Determination of Kidney Function
Related Studies:
Other Kidney Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Evaluation of New Test Method to Measure Kidney Function
|
|
|
|
|
|
|
|
